Search Results for: covid-19
Articles
Codiak BioSciences & CEPI Partner to Develop Broadly Protective Betacoronavirus Vaccine July 5, 2022
CEPI, the Coalition for Epidemic Preparedness Innovations, and Codiak BioSciences recently announced the latest funding award under CEPI’s US $200 million program to advance the development of vaccines that provide broad protection against….
DFE Pharma Expands its Inhalation Portfolio With New Launch July 5, 2022
DFE Pharma recently announced the expansion of its Dry Powder Inhalation (DPI) portfolio with the launch of Lactohale 400. The addition of Lactohale 400 further enhances the completeness of DFE Pharma’s portfolio of inhalation-grade lactose…..
US Government to Support Expansion of Croda Lipid Systems Capability June 29, 2022
Croda International Plc recently announced it has entered into a cooperative agreement with the US government in which the government will provide up to $75 million to expand the….
Soligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Synthetic Hypericin in the Treatment of Psoriasis June 28, 2022
Soligenix, Inc. recently announced the US FDA has cleared the Investigational New Drug (IND) application for a Phase 2a clinical...Acer Therapeutics & Relief Therapeutics Announce Update on US FDA Review of NDA June 21, 2022
Acer Therapeutics Inc. and its collaboration partner, Relief Therapeutics recently announced the US FDA has issued a Complete Response Letter...Valneva & Pfizer Enter Equity Subscription Agreement & Update Terms of Collaboration Agreement for Lyme Disease Vaccine Candidate June 20, 2022
Valneva SE and Pfizer Inc. recently announced they have entered into an Equity Subscription Agreement and have updated the terms of their Collaboration and License Agreement for Lyme disease vaccine candidate VLA15…..
VYNE Therapeutics Completes Enrollment in Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis June 17, 2022
VYNE Therapeutics Inc. recently announced the completion of enrollment in the Phase 2a study of FMX114 for the treatment of...Aeterna Zentaris Achieves Proof-of-Concept for the Treatment of NMOSD With AIM Biologicals Program June 14, 2022
Aeterna Zentaris Inc. recently announced its Autoimmunity Modifying (AIM) Biologicals program has achieved preclinical proof-of-concept for the potential treatment of...ProteoGenix, Aseem Healthcare & Trident Biopharm Solutions Announce New Antibody Cocktail Effective Against Major Variants of SARS-CoV-2 June 7, 2022
ProteoGenix, Aseem Healthcare, and Trident Biopharm Solutions recently announced the development of a new antibody cocktail effective against major variants...SPECIAL ROUNDTABLE - Which Trends Will Have the Most Impact on Drug Development in 2022? June 6, 2022
Drug Development & Delivery posed this question to life science leaders during a recent roundtable discussion. While their responses are varied, a common theme is that COVID-19 has left a lasting impact on the industry….
Jubilant HollisterStier Enters Cooperative Agreement With US Government to Expand Critical Vaccine Manufacturing Capacity June 3, 2022
Jubilant Pharmova Limited recently announced that Jubilant Pharma Limited, a wholly owned subsidiary of the company, through one of its wholly owned subsidiaries, Jubilant HollisterStier LLC, (JHS) a leading US-based….
Evonik Invests $220 Million to Build New Lipid Production Facility for mRNA-based Therapies in the US June 2, 2022
Evonik is building a new, highly flexible, global-scale production facility for pharmaceutical lipids in the US. The new plant at...SPECIAL FEATURE - Outsourcing Formulation Development & Manufacturing: Understanding Critical Attributes Earlier in Development Leads to a More Robust Drug Product June 1, 2022
Contributor Cindy H. Dubin speaks with industry leaders on how drug sponsors and CDMOs are collaborating earlier, and highlights how third-party contractors are navigating material shortages and how the industry is shifting to address different therapeutic targets and molecules, such as mRNA.
GLOBAL REPORT – 2021 Global Drug Delivery & Formulation Report: Part 3, Drug Delivery and Formulation Pipeline Trends June 1, 2022
In part 3 of this 3-part series, PharmaCircle, in collaboration with Drug Development & Delivery, provides additional insights into the nature of the current pipeline in terms of development phase, delivery route, molecule type, and disease area taken from PharmaCircle’s Pipeline Dynamics module.
EXECUTIVE INTERVIEW - BIOVECTRA: mRNA & the Future of Pharma June 1, 2022
Marc Sauer, PhD, discusses his new position, growth at BIOVECTRA, and how he believes mRNA technologies can best be leveraged to improve the lives of patients.
EXECUTIVE INTERVIEW - Catalent: Developing & Delivering Billions of Doses of Drugs Every Year June 1, 2022
Alessandro Maselli, President and Chief Operating Officer of Catalent, talks about his company’s unique approach to drug development partnerships as he prepares to become the company’s new President and Chief Executive Officer on July 1, 2022.
CLINICAL TRIALS SOLUTIONS - Cracking Down on the Rising Costs of Drug Development: How Pinpointing the Complexity of Individual Patients Can Improve Success Rates June 1, 2022
Dominique Demolle, PhD, and Erica Smith, PhD, say taking a more holistic, patient-centric approach by considering patients’ individual psychology, perceptions, and beliefs provides drug developers the opportunity to quantify these interpersonal differences between patients and address this source of variability in data analysis and interpretation.
ISR Signs Agreement With Gerresheimer for Clinical-Scale Production of IcoOne Nasal Inhalers May 31, 2022
The drug development company ISR has recently signed an agreement with Gerresheimer for large-scale production of the IcoOne nasal inhaler, for its Phase 3 study of its dry powder….
DFE Pharma Opens New Center of Excellence in India to Provide Fast-Track Formulation Services May 26, 2022
DFE Pharma recently announced the launch of its new Center of Excellence Closer to the Formulator (C2F) in Hyderabad, India. The C2F center is based in Genome Valley….
Oncotelic Therapeutics Receives FDA Clearance for Phase 2 Clinical Trial of OT-101/Pembroluzimab Combination for Mesothelioma (M201) May 25, 2022
Oncotelic Therapeutics, Inc. recently announced the clearance of the Phase 2 clinical trial protocol for mesothelioma after filing the protocol...
